William J Phd Link
CIK 1228684 · last filed 2026-09-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OYST price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1650
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TARS | Director | 94,553 | $70.03 | $6.62M | -$6.94M | 22 | 2026-09-17 |
| RXST | Director | 96,140 | $4.93 | $474.0K | -$903.1K | 17 | 2026-06-18 |
| LNSR | Director | 568,062 | $5.96 | $3.39M | $0 | 7 | 2026-06-05 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Director | 38,008 | $11.17 | $424.5K | -$7.72M | 9 | 2022-01-07 |
| GKOS | Director | 58,300 | $178.27 | $10.39M | -$7.62M | 17 | 2021-06-07 |
| EW | Director | 51,162 | $90.56 | $4.63M | -$7.03M | 15 | 2020-05-11 |
| Vivani Medical, Inc. (EYESW) Delisted | Director | 4,608,161 | $0.22 | $1.01M | $0 | 3 | 2019-06-05 |
| EYES | Director | 564,453 | $30.93 | $17.46M | $0 | 2 | 2016-06-03 |
| INGN | Director | 3,695,816 | $7.08 | $26.17M | $0 | 1 | 2014-02-21 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | 10%+ Owner | 10,709,818 | — | — | $4.38M | 1 | 2009-09-21 |
| INTRALASE CORP (ILSE) Delisted | Director | 2,338,482 | — | — | -$6.13M | 1 | 2007-01-17 |
Recent Filings · Page 2 of 11
105 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-15 | TARS | Notice (144) | −10,446 | -$846.3K | EDGAR |
| 2025-12-15 | TARS | Notice (144) | −12,500 | -$1.02M | EDGAR |
| 2025-09-18 | TARS | Gift (G) | −2,000 | $0 | EDGAR |
| 2025-09-10 | TARS | Sell (S) | −27,116 | -$1.55M | EDGAR |
| 2025-09-08 | TARS | Notice (144) | −27,116 | -$1.55M | EDGAR |
| 2025-06-16 | TARS | Mixed | +3,350 | $0 | EDGAR |
| 2025-06-04 | RXST | Grant (A) | +10,752 | $0 | EDGAR |
| 2025-05-28 | LNSR | Grant (A) | +7,374 | $0 | EDGAR |
| 2024-08-14 | TARS | Mixed | −72,330 | -$913.0K | EDGAR |
| 2024-06-25 | TARS | Exer (M) | +3,350 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.